Donaldson Inc Stock Price, News & Analysis

Isolere Bio by Donaldson has announced the availability of its manufacturing-grade IsoTag™ AAV reagent for purifying Adeno-associated Virus (AAV) vectors. The product now includes validated processes and comprehensive documentation, including a Regulatory Support File and FDA-acknowledged Drug Master File (DMF).

The technology, based on liquid-liquid phase separation developed at Duke University's Chilkoti Lab, combines affinity- and size-based separations using a recombinant protein. The company began select collaborations in 2021, made the product commercially available in 2023, and released the research-grade version in October 2024.

This advancement aims to address bottlenecks in GMP manufacturing and streamline purification processes for AAV-based gene therapies. The company will showcase the technology at ASGCT in New Orleans from May 13-17, featuring presentations on neutral pH elution of AAV and liquid-phase affinity purification technologies.

Donaldson Company (NYSE:DCI) has published its Fiscal Year 2024 Sustainability Report, highlighting significant progress in environmental and social initiatives. The company achieved an 18% reduction in Scope 1 and 2 GHG emissions (over 20,400 mt CO2e) compared to FY21 baseline, advancing toward their 2030 target of 42% reduction.

Key accomplishments include completing 134 energy efficiency projects globally and implementing a large-scale solar Virtual Power Purchase Agreement. The Donaldson Foundation contributed $1.2 million in FY24, reaching $3.6 million in cumulative donations since FY22. The company introduced a new initiative targeting a reduction of 3,200 metric tons in landfill waste.

However, operational safety faced challenges with seven life-changing events reported, an increase of three compared to FY23. The sustainability strategy 'Filtration for a Thriving Future' focuses on carbon reduction, resource efficiency, operational resiliency, and community engagement, supporting business growth through cost reduction, supply chain competitiveness, and stronger customer relationships.

Ginkgo Bioworks (NYSE: DNA) has secured a $29 million contract from ARPA-H for a two-year program called WHEAT (Wheat-based High efficiency Enzyme and API Technology). The project, in partnership with Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals, and Isolere Bio by Donaldson, aims to develop a revolutionary pharmaceutical manufacturing process.

The initiative focuses on creating distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems. This innovative approach seeks to shift API production from global supply chains to a decentralized system using Cell-Free Protein Synthesis (CFPS), potentially reshoring and stabilizing supply chains for essential medicines.

The WHEAT program will demonstrate scalable processes for CFPS-based production of complex APIs, with applications ranging from small molecule compounds to biologics like growth factors and insulin. Ginkgo will contribute its cell programming platform, utilizing machine learning and computational tools to engineer enzymes and optimize cell-free expression systems.

Donaldson Company (NYSE: DCI), a global leader in filtration products and solutions, announced that Tod Carpenter, chairman, president, and CEO, will present at the Raymond James 46th Annual Institutional Investors Conference in Orlando, Florida. The presentation is scheduled for Monday, March 3, at 3:35 p.m. CT.

Founded in 1915, Donaldson operates through three primary segments: Mobile Solutions, Industrial Solutions, and Life Sciences. The company maintains a presence in over 140 locations across six continents, partnering with diverse customers ranging from small business owners to R&D organizations and major OEM brands.

Donaldson Company (NYSE: DCI) reported second quarter fiscal 2025 results with sales of $870.0 million, down 0.8% year over year but up 0.9% in constant currency. GAAP earnings per share (EPS) decreased 2.2% to $0.79, while adjusted EPS grew 2.5% to $0.83.

The company showed mixed performance across segments:

• Mobile Solutions segment saw Aftermarket sales increase 4.0%, while Off-Road and On-Road sales declined 12.8% and 24.4% respectively
• Industrial Solutions segment decreased 3.7%, though Aerospace and Defense grew 18.7%
• Life Sciences segment increased 9.2%

For fiscal 2025, Donaldson narrowed its adjusted EPS guidance to between $3.60 and $3.68, expecting sales to be flat to up 4% compared to prior year. The company maintains its commitment to shareholder returns, having paid $64.6 million in dividends and repurchased 0.9% of outstanding shares for $81.4 million year-to-date.

Donaldson Company (NYSE: DCI), a global filtration technology leader, has announced its upcoming second quarter fiscal 2025 earnings conference call. The event will be webcast live on Thursday, February 27, 2025, at 9:00 a.m. CT.

Investors can access the live webcast through the 'Events & Presentations' section of Donaldson's Investor Relations website at IR.Donaldson.com. A replay will be available in the same section starting at approximately 12:00 p.m. CT on the same day.

Founded in 1915, Donaldson operates through three primary segments: Mobile Solutions, Industrial Solutions, and Life Sciences, serving diverse industries with technology-led filtration solutions across over 140 locations on six continents.

Donaldson Company (NYSE: DCI) announced a partnership with Daimler Truck North America (DTNA) for their hydrogen fuel cell project. Donaldson's advanced air filter technology will be featured in the next-generation Freightliner SuperTruck III, part of the U.S. Department of Energy's (DOE) initiative to enhance fuel efficiency and reduce emissions in heavy-duty Class 8 long-haul trucks.

The SuperTruck program, which began in 2011, has evolved from optimizing diesel engines in its first two phases to now developing a hydrogen fuel cell truck demonstrator. DTNA has received $26 million in DOE funding for this project. The partnership builds on Donaldson and DTNA's existing collaboration on filtration solutions for commercial vehicles, with the field experience expected to accelerate the adoption of on-highway hydrogen fuel cell applications.

Donaldson Company (NYSE: DCI) has declared a quarterly cash dividend of 27.0 cents per share, payable on February 28, 2025, to shareholders of record as of February 13, 2025. The company, a member of the S&P High-Yield Dividend Aristocrats Index, has marked its 29th consecutive year of annual dividend increases in 2024. Notably, Donaldson has maintained its tradition of paying quarterly cash dividends for 69 years.

Founded in 1915, Donaldson is a global leader in technology-led filtration products and solutions, operating through three primary segments: Mobile Solutions, Industrial Solutions, and Life Sciences. The company maintains a presence in over 140 locations across six continents, serving diverse industries and advanced markets.

Donaldson Company (NYSE: DCI) reported record first quarter fiscal 2025 results with sales of $900.1 million, up 6.4% year-over-year. GAAP earnings reached $99.0 million with EPS of $0.81, increasing 8.1% from prior year, while adjusted EPS was $0.83.

The company saw growth across all segments: Mobile Solutions up 6.0%, Industrial Solutions up 4.6%, and Life Sciences up 16.6%. Gross margin was 35.5%, slightly down from 35.6% in 2024. The company reaffirmed its fiscal 2025 outlook, projecting adjusted EPS between $3.56 and $3.72, with sales expected to increase 2-6% year-over-year.